Cargando…
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of trea...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786012/ https://www.ncbi.nlm.nih.gov/pubmed/25936599 http://dx.doi.org/10.1016/j.ijrobp.2015.02.048 |
_version_ | 1782420485031591936 |
---|---|
author | Oberije, Cary De Ruysscher, Dirk Houben, Ruud van de Heuvel, Michel Uyterlinde, Wilma Deasy, Joseph O. Belderbos, Jose Dingemans, Anne-Marie C. Rimner, Andreas Din, Shaun Lambin, Philippe |
author_facet | Oberije, Cary De Ruysscher, Dirk Houben, Ruud van de Heuvel, Michel Uyterlinde, Wilma Deasy, Joseph O. Belderbos, Jose Dingemans, Anne-Marie C. Rimner, Andreas Din, Shaun Lambin, Philippe |
author_sort | Oberije, Cary |
collection | PubMed |
description | PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration of multiple models. The current study takes the first step in this process by developing and validating a model that can provide physicians with a survival probability for an individual NSCLC patient. METHODS AND MATERIALS: Data from 548 patients with stage III NSCLC were available to enable the development of a prediction model, using stratified Cox regression. Variables were selected by using a bootstrap procedure. Performance of the model was expressed as the c statistic, assessed internally and on 2 external data sets (n=174 and n=130). RESULTS: The final multivariate model, stratified for treatment, consisted of age, gender, World Health Organization performance status, overall treatment time, equivalent radiation dose, number of positive lymph node stations, and gross tumor volume. The bootstrapped c statistic was 0.62. The model could identify risk groups in external data sets. Nomograms were constructed to predict an individual patient’s survival probability (www.predictcancer.org). The data set can be downloaded at https://www.cancerdata.org/10.1016/j.ijrobp.2015.02.048. CONCLUSIONS: The prediction model for overall survival of patients with stage III NSCLC highlights the importance of combining patient, clinical, and treatment variables. Nomograms were developed and validated. This tool could be used as a first building block for a decision support system. |
format | Online Article Text |
id | pubmed-4786012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
record_format | MEDLINE/PubMed |
spelling | pubmed-47860122016-03-10 A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients Oberije, Cary De Ruysscher, Dirk Houben, Ruud van de Heuvel, Michel Uyterlinde, Wilma Deasy, Joseph O. Belderbos, Jose Dingemans, Anne-Marie C. Rimner, Andreas Din, Shaun Lambin, Philippe Int J Radiat Oncol Biol Phys Article PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration of multiple models. The current study takes the first step in this process by developing and validating a model that can provide physicians with a survival probability for an individual NSCLC patient. METHODS AND MATERIALS: Data from 548 patients with stage III NSCLC were available to enable the development of a prediction model, using stratified Cox regression. Variables were selected by using a bootstrap procedure. Performance of the model was expressed as the c statistic, assessed internally and on 2 external data sets (n=174 and n=130). RESULTS: The final multivariate model, stratified for treatment, consisted of age, gender, World Health Organization performance status, overall treatment time, equivalent radiation dose, number of positive lymph node stations, and gross tumor volume. The bootstrapped c statistic was 0.62. The model could identify risk groups in external data sets. Nomograms were constructed to predict an individual patient’s survival probability (www.predictcancer.org). The data set can be downloaded at https://www.cancerdata.org/10.1016/j.ijrobp.2015.02.048. CONCLUSIONS: The prediction model for overall survival of patients with stage III NSCLC highlights the importance of combining patient, clinical, and treatment variables. Nomograms were developed and validated. This tool could be used as a first building block for a decision support system. 2015-04-30 2015-07-15 /pmc/articles/PMC4786012/ /pubmed/25936599 http://dx.doi.org/10.1016/j.ijrobp.2015.02.048 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Oberije, Cary De Ruysscher, Dirk Houben, Ruud van de Heuvel, Michel Uyterlinde, Wilma Deasy, Joseph O. Belderbos, Jose Dingemans, Anne-Marie C. Rimner, Andreas Din, Shaun Lambin, Philippe A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
title | A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
title_full | A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
title_fullStr | A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
title_full_unstemmed | A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
title_short | A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
title_sort | validated prediction model for overall survival from stage iii non-small cell lung cancer: toward survival prediction for individual patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786012/ https://www.ncbi.nlm.nih.gov/pubmed/25936599 http://dx.doi.org/10.1016/j.ijrobp.2015.02.048 |
work_keys_str_mv | AT oberijecary avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT deruysscherdirk avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT houbenruud avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT vandeheuvelmichel avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT uyterlindewilma avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT deasyjosepho avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT belderbosjose avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT dingemansannemariec avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT rimnerandreas avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT dinshaun avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT lambinphilippe avalidatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT oberijecary validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT deruysscherdirk validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT houbenruud validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT vandeheuvelmichel validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT uyterlindewilma validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT deasyjosepho validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT belderbosjose validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT dingemansannemariec validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT rimnerandreas validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT dinshaun validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients AT lambinphilippe validatedpredictionmodelforoverallsurvivalfromstageiiinonsmallcelllungcancertowardsurvivalpredictionforindividualpatients |